Literature DB >> 582213

Plasma levels of apomorphine following intravenous, intraperitoneal and oral administration to mice and rats.

R V Smith, R E Wilcox, W H Soine, W H Riffee, R J Baldessarini, N S Kula.   

Abstract

Clinical use of the potent dopaminergic partial-agonist apomorphine (APO) in a wide variety of neuropsychiatric disorders is hampered by a lack of data concerning tissue/plasma levels following various routes of administration. In the present experiments, plasma levels were assessed at various times up to 4 hours after APO administration IV, IP, and PO to mice and rats. Plasma levels of total radioactivity after PO administration of [3H]-APO were 50 to 65% of those seen after IV administration, but brain levels were almost undetectable after PO administration. Organic solvent-extractable concentrations of tritium-labelled material after IV and IP administration of [3H]-APO to mice were significantly lower than the levels of total radioactivity, while after PO administration, these concentrations were minimal. Similar results were observed in rats following IV and PO administration of [3H]-APO.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 582213

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  9 in total

1.  Repeated apomorphine administration alters dopamine D1 and D2 receptor densities in pigeon basal telencephalon.

Authors:  Martin J Acerbo; Pavel Výboh; Lubor Kostál; Lubica Kubíková; Juan D Delius
Journal:  Exp Brain Res       Date:  2004-12-15       Impact factor: 1.972

2.  Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats.

Authors:  A G Molloy; J L Waddington
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

3.  Effects of multiple pretreatment with apomorphine and amphetamine on amphetamine-induced locomotor activity and its inhibition by apomorphine.

Authors:  W H Riffee; R E Wilcox
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Behavioral facilitation following chronic administration of N-n-propylnorapomorphine.

Authors:  R E Wilcox; W H Riffee; P C Chen; S Hammett; R V Smith
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

5.  A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.

Authors:  Mitsuharu Ueda; Masamitsu Okada; Mineyuki Mizuguchi; Barbara Kluve-Beckerman; Kyosuke Kanenawa; Aito Isoguchi; Yohei Misumi; Masayoshi Tasaki; Akihiko Ueda; Akinori Kanai; Ryoko Sasaki; Teruaki Masuda; Yasuteru Inoue; Toshiya Nomura; Satoru Shinriki; Tsuyoshi Shuto; Hirofumi Kai; Taro Yamashita; Hirotaka Matsui; Merrill D Benson; Yukio Ando
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

6.  Dopamine receptor sensitivity after chronic dopamine agonists. Striatal 3H-spiroperidol binding in mice after chronic administration of high doses of apomorphine, N-n-propylnorapomorphine and dextroamphetamine.

Authors:  W H Riffee; R E Wilcox; D M Vaughn; R V Smith
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval.

Authors:  R Castro; P Abreu; C H Calzadilla; M Rodriguez
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Age difference in apomorphine-induced stereotypy in rats: relationship to plasma and brain concentrations.

Authors:  H Watanabe; S Nakano; N Ogawa
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Effects of apomorphine and piribedil on pentylenetetrazol-induced seizures in mice.

Authors:  W H Riffee; R E Wilcox; C P Goldman; R V Smith
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.